Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced today that it has entered into a research collaboration and license agreement with Genmab to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications.